Physician profile
Lee Ouyang
NPI 1497296750
$2,845.56
in general payments reported to CMS, 2019-2025
26 companies · $556 in 2025
The $556 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $222 · 2022: $643 · 2023: $631 · 2024: $793 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,789 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,788.67 |
| Education | $191.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $543.03 | 2023-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $279.07 | 2022-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Acessa Provu System |
| Abbvie INC. | $225.13 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $214.67 | 2023-2024 | Myfembree |
| Intuitive Surgical, INC. | $208.98 | 2021 | |
| Organon LLC | $203.96 | 2022-2025 | Nexplanon |
| Shield Therapeutics INC | $171.46 | 2023-2025 | Accrufer |
| Daiichi Sankyo INC. | $132.20 | 2024-2025 | Injectafer |
| Mayne Pharma Commercial LLC | $113.12 | 2022-2025 | |
| Exeltis, USA INC. | $112.38 | 2022-2025 | Slynd |
| Astrazeneca Pharmaceuticals Lp | $111.88 | 2025 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $83.91 | 2022-2023 | |
| Myovant Sciences INC. | $83.12 | 2022 | |
| Pfizer INC. | $56.37 | 2021-2024 | |
| Coopersurgical, INC. | $45.92 | 2024-2025 | Paragard T 380a, Ally II Ups |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karl Storz Endoscopy-America | $43.39 | 2022 | |
| Novo Nordisk INC | $37.26 | 2025 | Wegovy |
| Mycovia Pharmaceuticals, INC. | $28.41 | 2022-2023 | Vivjoa |
| Minerva Surgical, INC | $27.02 | 2022 | |
| Davol INC. | $25.94 | 2022 | |
| Biogen, INC. | $22.75 | 2025 | Zurzuvae |
| Sanara Medtech INC. | $18.61 | 2025 | Celleraterx |
| Meditrina | $15.48 | 2024 | |
| Optumhealth Care Solutions, LLC | $15.16 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Scynexis, INC. | $14.09 | 2022 | |
| Aspira Women'S Health INC | $12.25 | 2024 | Ova1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Ouyang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.